Get started
Author

Valentina L. Ivanova

Observed names: V L Ivanova, V. Ivanova, V. L. Ivanova, Valentina Ivanova, Valentina L Ivanova
Institution: Botkin Hospital
ORCID: 0000-0001-9272-1742
Observed ORCID: 0000-0001-9272-1742
OpenAlex ID: A5113714708
Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial
2013 · Jesus San Miguel, Katja Weisel, et al. · The Lancet Oncology · 801
Cytogenetics and long-term survival of patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide and low-dose dexamethasone
2015 · M. A. Dimopoulos, K. C. Weisel, et al. · Haematologica · 72
PDF
Maintenance with rituximab is safe and not associated with severe or uncommon infections in patients with follicular lymphoma: results from the phase IIIb MAXIMA study
2014 · Mathias Witzens-Harig, Robin Foá, et al. · Annals of Hematology · 31
Analysis of renal impairment in MM-003, a phase III study of pomalidomide + low - dose dexamethasone versus high - dose dexamethasone in refractory or relapsed and refractory multiple myeloma
2016 · K. C. Weisel, M. A. Dimopoulos, et al. · Haematologica · 21
PDF
Final Analysis, Cytogenetics, Long-Term Treatment, and Long-Term Survival In MM-003, A Phase 3 Study Comparing Pomalidomide + Low-Dose Dexamethasone (POM + LoDEX) Vs High-Dose Dexamethasone (HiDEX) In Relapsed/Refractory Multiple Myeloma (RRMM)
2013 · Meletios A. Dimopoulos, Katja Weisel, et al. · Blood · 17
Application of PRV-1 mRNA expression level and JAK2V617F mutation for the differentiating between polycytemia vera and secondary erythrocytosis and assessment of treatment by interferon or hydroxyurea
2007 · V. Tutaeva, A. V. Misurin, et al. · Hematology · 10
PDF
Maintenance Rituximab Every 2 Months for 2 Years Is Effective and Well Tolerated In Patients with Follicular Lymphoma with Both Standard or Rapid Infusion: Updated Results From the Phase IIIb MAXIMA Study
2010 · Robin Foá, Alice Di Rocco, et al. · Blood · 7
Erratum to: Maintenance with rituximab is safe and not associated with severe or uncommon infections in patients with follicular lymphoma: results from the phase IIIb MAXIMA study
2014 · Mathias Witzens-Harig, Robin Foá, et al. · Annals of Hematology · 5
PDF
MM-003 Phase 3 Study Of Pomalidomide In Combination With Low-Dose Dexamethasone (POM + LoDEX) Vs High-Dose Dexamethasone (HiDEX) In Relapsed/Refractory Multiple Myeloma (RRMM): POM + Lodex Is Beneficial For Elderly Patients (> 65 Years of Age)
2013 · Katja Weisel, Jesús F. San Miguel, et al. · Blood · 5
Patient Outcomes By Prior Therapies and Depth Of Response: Analysis Of MM-003, a Phase 3 Study Comparing Pomalidomide + Low-Dose Dexamethasone (POM + LoDEX) Vs High-Dose Dexamethasone (HiDEX) In Relapsed/Refractory Multiple Myeloma (RRMM)
2013 · Jesús F. San Miguel, Katja Weisel, et al. · Blood · 5
[The detection of minimal residual disease in patients with chronic B-cell lymphatic leukemia using patient-specified polymerase chain reaction].
2011 · Iu V Sidorova, T V Sorokina, et al. · PubMed · 4
Safety and Efficacy in Patients Receiving Maintenance Rituximab for Follicular Lymphoma: Early Results From Phase IIIb MAXIMA Trial.
2009 · Mathias Witzens-Harig, Guy van Hazel, et al. · Blood · 4
Evolution of Platelet Function and Bleeding in Children and Adults with Chronic Immune Trombocytopenia on Romiplostim Treatment
2017 · Anastasia A. Ignatova, Е. В. Сунцова, et al. · Blood · 3
Ibrutinib in the Treatment of Refractory Chronic Lymphocytic Leukemia
2017 · Evgenii Aleksandrovich Nikitin, E. A. Dmitrieva, et al. · Clinical oncohematology · 3
The MAXIMA Study: Safety of Rituximab (MabThera®) Maintenance Therapy in Patients with Follicular Non-Hodgkin’s Lymphoma Who Have Responded to Induction Therapy.
2007 · Michael K. Wenger, Robin Foa, et al. · Blood · 3
Possibilities of targeted therapy for myelofibrosis: Moscow experience
2022 · O. Yu. Vinogradova, M. M. Pankrashkina, et al. · Oncohematology · 2
PDF
Ibrutinib Monotherapy in Patients with Relapsed/Refractory Mantle Cell Lymphoma in Community Clinical Practice Outside of Clinical Trials
2019 · Vladimir I. Vorobyev, Vera A. Zherebtsova, et al. · Blood · 2
Incidence of Primary Immune Thrombocytopenia (ITP) in Adults in One Region of Russia
2016 · Anait L. Melikyan, Elena I Pustovaya, et al. · Blood · 2
Combination of bendamustine and rituximab in the management of relapsed and refractory chronic lymphocytic leukemia: the results of retrospective study
2015 · S. V. Semochkin, E. G. Arshanskaya, et al. · Oncohematology · 2
Efficacy and Safety Of Pomalidomide Plus Low-Dose Dexamethasone In Advanced Multiple Myeloma: Results Of Randomized Phase 2 and 3 Trials (MM-002/MM-003)
2013 · David S. Siegel, Paul G. Richardson, et al. · Blood · 2
Carfilzomib, lenalidomide and dexamethasone in relapsed/refractory multiple myeloma patients: the real-life experience
2021 · Vera A. Zherebtsova, Vladimir I. Vorobyev, et al. · Terapevticheskii arkhiv · 1
PDF
Efficiency of interferon therapy in patients with essential thrombocythemia or polycythemia vera
2016 · M A Sokolova, A G Turkina, et al. · Terapevticheskii arkhiv · 1
Long-Term Outcomes of Dasatinib Therapy in Patients with Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia from Physician’s and Patient’s Perspective
2014 · Tatyana I Ionova, Tatyana P Nikitina, et al. · Blood · 1
Data From The Russian Cohort Of The International Disease Registry For Paroxysmal Nocturnal Hemoglobinuria (PNH)
2013 · Igor Lisukov, Alexander Kulagin, et al. · Blood · 1
Clinical and Patient-Reported Outcomes of Dasatinib Therapy in Patients with Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia
2012 · Tatyana I Ionova, Tatiana P Nikitina, et al. · Blood · 1
Works count: 39
Citation count: 1,006
H-index: 7
I10-index: 6
Year
Topic
Type